Myoma

07/01/1995 - "Gonadotropin-releasing hormone agonist-treated patients had a significant reduction in uterine and myoma volume when compared with the placebo group (P < .01). "
06/01/2009 - "More than 80% of women in this study benefited from the use of GnRH agonist to produce menopause, suggesting that this can be an alternative choice for managing perimenopausal women with symptomatic uterine myomas."
08/15/1985 - "Luteinizing hormone-releasing hormone agonist is the first medication demonstrated effective in reducing the size of uterine myomas."
02/01/1992 - "Clinical trials with gonadotropin-releasing hormone agonists consistently have demonstrated efficacy for decreasing both myoma size and uterine volume. "
09/01/2000 - "Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women."

11/01/2008 - "Levonorgestrel-releasing intrauterine system use in uterine myomas. "
11/01/2008 - "The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study."
10/01/2006 - "The use of levonorgestrel - IUD in the treatment of uterine myoma in Thai women."
07/01/1999 - "This case report focuses on the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on uterine myomas in a renal transplant patient. "
07/01/1999 - "Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient."

10/01/2000 - "Traditionally, estrogen has been considered the major promoter of myoma growth. "
01/01/1995 - "Traditionally, estrogen has been considered the major promoter of myoma growth. "
01/01/1990 - "Dissimilar distribution patterns of immunoreactive, estrogen-nonbinding ER in leiomyomata and normal myometria suggest that an impaired metabolism of ER may contribute to myoma growth."
06/01/1989 - "These results suggest that myoma contains more ER positive cells to obtain estrogen effects than myometrium."
01/01/1989 - "Apropos of 7 cases of myoma that appeared while under anti-estrogen treatment]."

01/01/2002 - "Triptoreline is a GnRHa which has been found to be effective in reducing myoma volume, but this effect could not be deactivated with tibolone. "
01/01/2000 - "Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas."
10/31/2001 - "The aim of the present study is to evaluate the long term effects of Tibolone (Livial) on uterine myomas volume as well as on uterine arteries pulsatility index (PI) in postmenopausal women. "
01/01/2014 - "The median myoma volume decreased upon iCR by as much as -30% (P = 0.016) but increased upon tibolone by +4.7%. "
12/01/2001 - "In conclusion, tibolone has no significant effect on myoma size in postmenopausal women. "

09/01/2011 - "To compare these data in a case-control study, we analyzed a matched control group of 12 patients treated with leuprolide acetate (1.88 mg monthly) for 6 months having uterine myoma. "
04/01/1997 - "Leuprolide-treated myomas."
09/01/1995 - "Leuprolide acetate treatment and myoma arterial size."
02/01/1995 - "Myoma size and location were assessed by endovaginal ultrasound before preoperative treatment with depot leuprolide. "
01/01/1994 - "[Size reduction of uterine myomas with monthly administered leuprolide acetate]."

12/01/2021 - "Conclusion: Vitamin D supplementation may not be effective in women with vitamin D insufficiency or deficiency in the short term to reduce myoma size."
12/01/2021 - "This study aimed to evaluate the effect of vitamin D supplements on the size of myoma in women with vitamin D insufficiency or deficiency. "
12/01/2021 - "Effect of Two Different Doses of Vitamin D Supplementation on Uterine Myoma on South East Iranian Population: A Clinical Trial."
01/01/2020 - "The combined supplementation of vitamin D and EGCG seems to be an optimal approach for the management of myomas and correlated symptoms. "
01/01/2020 - "Our aim was to verify the effect of combined oral vitamin D and EGCG supplementation in symptomatic women with myomas. "

01/01/2014 - "As a result, mifepristone single-treated group represents the most significant reduction in myoma cell viability and proliferation. "
11/01/2008 - "To estimate the efficacy of daily administration of 5 mg compared with 10 mg of mifepristone for the treatment of uterine myomas. "
05/01/2005 - "Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas."
06/01/2013 - "This study was undertaken to evaluate efficacy and safety of low dose mifepristone in medical management of myoma and to compare two doses - 10 vs. 25 mg/day. "
11/01/2015 - "Low-Dose Mifepristone Versus Placebo to Treat Uterine Myoma: A Double-Blind, Randomized Clinical Trial."

09/01/2014 - "On the other hand, recent studies have demonstrated the efficacy of ulipristal acetate in the medical management of myomas. "
07/01/2020 - "Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases."
02/01/2020 - "The clinical question in "PICO" format was in patients affected by uterine myomas undergoing operative hysteroscopic management, "Does UPA impact the surgical outcomes?" We performed a systematic literature search in PubMed/MEDLINE and Embase for original studies written in English (registered in PROSPERO CRD42018092201), using the terms "hysteroscopy" AND "ulipristal acetate" published up to March 2019. "
08/01/2015 - "To study the in vivo mechanisms of action of ulipristal acetate (UPA) on uterine myomas. "
03/01/2022 - "Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study."

04/01/2008 - "Vasopressin (12 IU) injection around the myoma is a simple, effective, and safe homeostatic procedure during LM. "
02/01/2021 - "The study included 194 patients classified into two groups- 1) Vasopressin group: the vasopressin was diluted as 0.1 unit/ml and 15 ml was injected by the surgeon in the plane between the myometrium and the myoma. "
03/01/2019 - "Additionally, EBL was significantly lower in the vasopressin group in all of the study's subgroups of patients stratified according to the size and number of myomas. "
03/01/2019 - "The risk factors for prolongation of the procedure included size and number of myomas independently of vasopressin. "
01/01/2019 - "Submyometrial vasopressin injection before microwave ablation of vascular-rich submucosal myomas: a preliminary case study."

12/01/2011 - "Progestins, although used widely, remain poorly effective as they promote myoma cell growth. "
09/11/1993 - "Resection of submucosal myoma usually enables treatment with progestins to be discontinued. "
12/15/1966 - "Induction of degenerative changes in uterine myomas by high-dosage progestin therapy."
01/01/1989 - "These results agree with the hypothesis that leiomyomas have a different etiology and may explain why some myomas decrease after progestin therapy (submucous), while others (subserosal) remain unchanged."
10/01/2007 - "Long-term use of progestogens--effects on endometriosis, adenomyosis and myomas."

11/01/2023 - "One year after myomectomy, most women have benefited from myomectomy, concluded by a significant number of women who experienced myoma-related symptom improvement, positive patient satisfaction, and a significant improvement in reported quality of life. "
11/01/2019 - "Most authors also found a significant improvement in urinary symptom scores after myomectomy and myomas embolization. "
03/01/1999 - "Hysteroscopic myomectomy is the best treatment of women with submucous myoma."
05/01/2020 - "In the current study, injection of PGF2α was beneficial for 1-step complete resection of large (>5 cm) submucous myomas via hysteroscopic myomectomy."
07/27/2023 - "While hysteroscopic myomectomy is considered the gold standard treatment for patients experiencing symptoms from submucosal myomas, there are currently no specific guidelines available for managing type 3 myomas, and the optimal surgical approach remains uncertain. "

11/01/2013 - "Although it has been known that the treatment of submucous myomas results in a reduction of MBL, this is the first study to show that radiofrequency ablative therapy for intramural myomas without a submucosal component will also result in a significant reduction in menstrual blood loss."
12/01/2021 - "Ultrasound-guided MWA is an effective and safe minimally invasive therapy for symptomatic uterine myomas."
01/01/2006 - "Myoma care may be improved through the introduction of new, safe, and effective therapies."
01/01/2019 - "To emphasize the efficacy of UAE as a uterus preserving treatment with targeted therapy of myomas only, analysis of tissue perfusion pre and post embolization is required. "
10/01/2014 - "As diagnosis tools, studies are revealing that ultrasound has been shown to be an insufficient method of myoma mapping, and magnetic resonance imaging should be preferred for surgical therapy planning. "

08/01/2004 - "Uterine artery embolization is associated with a significant reduction in myoma and uterine volume. "
08/01/2003 - "Selective uterine artery embolization is effective for uterine myoma. "
06/01/2013 - "Is uterine artery embolization for patients with large myomas safe and effective? "
03/01/2010 - "On the basis of consistent published scientific evidence, the American College of Obstetricians and Gynecologists has given uterine artery embolization (UAE) a level A recommendation as a viable alternative treatment for uterine myomas, describing it as a safe and effective option for appropriately selected women who wish to retain their uteri. "
03/01/2003 - "Uterine artery embolization could be useful in the treatment of myoma, either before surgery to facilitate dissection, or totally in place of surgery. "

07/01/2013 - "Hysterectomy is the most effective treatment for symptomatic myoma with no possible recurrence. "
03/01/2011 - "Myolysis is one of the procedures that is claimed to provide significant improvement in myoma status without hysterectomy. "
10/01/2008 - "Numerous procedures have been developed in recent decades that claim to provide significant improvement in myoma status without hysterectomy. "
01/01/2012 - "Efficacy of electrosurgical bipolar vessel sealing for abdominal hysterectomy with uterine myomas more than 14 weeks in size: a randomized controlled trial."
11/01/2007 - "The proposed transfusion-infusion programs in abdominal hysterectomy for large-sized myomas by applying blood-preserving methods are effective in avoiding the use of donor blood components and accordingly in reducing the frequency of complications associated with transfusions of donor blood components, and improving the postoperative period."

05/01/2005 - "Complete removal of the myoma led to better results (p = .039), which were further improved by endometrial ablation (p = .022). "
10/01/1999 - "This study compares results of endometrial ablation alone and in combination with myoma coagulation. "
12/26/2022 - "Effectiveness of microwave endometrial ablation combined with hysteroscopic transcervical resection in treating submucous uterine myomas."
05/19/2022 - "In Part III, the author reviews advanced resectoscopic procedures in which sonographic guidance is a requirement for the management of severe intrauterine adhesions and late-onset endometrial ablation failures, the management of FIGO Type 3 and 4 intramural myomas, as well as large submucous myomas."
01/01/2021 - "Procedures which involve greater precision and control-endomyometrial resection (EMR), hysteroscopic metroplasty, the correction of isthmoceles, the resection of intramural myomas, and the management of late-onset endometrial ablation failure-are only possible with the CFGR. "